Lin BioScience's lead drug candidate, LBS-007, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). This designation aims to expedite the development and review process for LBS-007, addressing a significant unmet medical need in patients with AML. The company is currently conducting a Phase 1/2 clinical trial to evaluate the safety and efficacy of LBS-007 in patients with relapsed or resistant acute leukemias across multiple sites in the US, Australia, and Taiwan.
Clinical Development and Safety Profile
The ongoing Phase 1/2 trial (NCT05756322) is designed to assess the safety, tolerability, and preliminary efficacy of LBS-007, both as a monotherapy and in combination with other agents such as venetoclax and azacitidine. Initial data from the Phase 1 dose-escalation phase indicate a promising safety profile. According to Dr. Irene Wang, President & CSO of Lin BioScience, no 'Definitely or Probably Related Adverse Effects' have been observed in patients receiving low to high doses of LBS-007.
Mechanism of Action and Preclinical Data
LBS-007 is a natural, non-ATP cell cycle inhibitor that targets a broad array of cancers by blocking the kinase activity of CDC7, a key regulator of the cancer cell cycle. By inhibiting CDC7, LBS-007 disrupts tumor cell proliferation and induces cancer cell death. Preclinical studies have demonstrated potent activity against leukemia and multiple solid tumors, particularly in chemotherapy-resistant cell lines.
Fast Track Designation Benefits
The FDA's Fast Track designation is designed to facilitate the development and accelerate the review of drugs that treat serious conditions and fill unmet medical needs. This designation provides Lin BioScience with several benefits, including more frequent meetings and written communication with the FDA, eligibility for Accelerated Approval and Priority Review, and the potential for Rolling Review, which allows the company to submit portions of its New Drug Application (NDA) as they become available.
Company Statements
Dr. Tom Lin, Chairman of Lin BioScience, stated, 'We are thrilled to see LBS-007 showing signs of early treatment response and potential efficacy in addressing this critical unmet medical need. Receiving FDA Fast Track Designation is a significant milestone, offering an expedited pathway to advance the development of this promising therapy. We remain deeply committed to delivering transformative solutions for patients in need.'
About Lin BioScience
Founded in 2016, Lin BioScience is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for cancer, ophthalmology, and metabolic diseases. In addition to LBS-007, the company's pipeline includes LBS-008 for geographic atrophy and Stargardt Disease, LBS-009 for non-alcoholic steatohepatitis (NASH), and LBS-002 for primary and metastatic brain cancers.
